EX-2.1 2 a17-20130_1ex2d1.htm EX-2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT Dated as of August 14, 2017 between JANSSEN PHARMACEUTICALS, INC. and CERECOR INC. Page DEFINITIONS; INTERPRETATION PURCHASE AND SALE REPRESENTATIONS AND WARRANTIES OF...Asset Purchase Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis Asset Purchase Agreement (this “Agreement”) dated as of August 14, 2017 is entered into between Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Buyer”), and Cerecor Inc., a Delaware corporation (“Seller”). Buyer and Seller are sometimes individually referred to herein as a “Party” and are sometimes collectively referred to herein as the “Parties”. Certain capitalized terms used herein have the meanings ascribed to them in Section 1.1.
ASSET PURCHASE AGREEMENT Dated as of August 14, 2017 between JANSSEN PHARMACEUTICALS, INC. and CERECOR INC.Asset Purchase Agreement • August 14th, 2017 • Cerecor Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 14th, 2017 Company Industry JurisdictionThis Asset Purchase Agreement (this “Agreement”) dated as of August 14, 2017 is entered into between Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Buyer”), and Cerecor Inc., a Delaware corporation (“Seller”). Buyer and Seller are sometimes individually referred to herein as a “Party” and are sometimes collectively referred to herein as the “Parties”. Certain capitalized terms used herein have the meanings ascribed to them in Section 1.1.